Aureum Diagnostics are delighted to announce the appointment of Dr John Shillingford to the board as a Norcliffe Capital investor representative.
For the past eight years, John has provided consultancy services to global firms on the development of clinical drug trials and MedTech devices. Until 2011 and its sale, he held senior global roles at Averion International Corporation, including President of Averion GmbH, President of Averion Europe and Executive Vice President and Global Head of Clinical Operations. Prior to Averion, he served as Managing Director and Vice President of Clinical Operations of Inform Gmbh. John has extensive experience of clinical trial design and implementation across the whole of Europe and has successfully commenced and managed operations in Central and Eastern Europe. He has worked in all phases of drug development and has managed clinical research projects in Eastern and Western Europe, North America on behalf of clients from Japan, the USA and Europe. He has over 40 years of Pharmaceutical and Contract Research industry experience. John is on the board of Afon Technology. In addition to his board duties, John’s role at Aureum Diagnostics is to oversee the clinical trial activities. His considerable expertise in this sector will ensure that all the trials are designed to strict guidelines to satisfy the appropriate global medical directives
Prof. David Onions, Chief Scientific Adviser to Norcliffe, said:
I am thrilled John is joining the Aureum team. He brings a tremendous depth of knowledge on guiding the development of medical devices through the regulatory maze. He is an insightful and thoughtful leader who will be a tremendous asset to the company.”